within Pharmacolibrary.Drugs.ATC.N;

model N04BA01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.5e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0019,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0005,
    k12             = 1.4,
    k21             = 1.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BA01_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Levodopa is a precursor of dopamine used primarily in the treatment of Parkinson's disease and parkinsonism. It is usually administered with carbidopa or benserazide to inhibit peripheral metabolism, allowing more levodopa to reach the brain. Levodopa remains an approved drug today and is a mainstay treatment for motor symptoms of Parkinson's disease.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, both sexes, after intravenous administration.</p><h4>References</h4><ol><li><p>Siddiqi, SH, et al., &amp; Black, KJ (2015). The Human Experience with Intravenous Levodopa. <i>Frontiers in pharmacology</i> 6 307–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2015.00307&quot;>10.3389/fphar.2015.00307</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26779024/&quot;>https://pubmed.ncbi.nlm.nih.gov/26779024</a></p></li><li><p>Hardie, RJ, et al., &amp; Allen, JG (1986). The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson&#x27;s disease who exhibit on-off fluctuations. <i>British journal of clinical pharmacology</i> 22(4) 429–436. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1986.tb02913.x&quot;>10.1111/j.1365-2125.1986.tb02913.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3533125/&quot;>https://pubmed.ncbi.nlm.nih.gov/3533125</a></p></li><li><p>Bergquist, F, et al., &amp; Eriksson, E (2024). Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion. <i>Movement disorders clinical practice</i> 11(9) 1095–1102. DOI:<a href=&quot;https://doi.org/10.1002/mdc3.14138&quot;>10.1002/mdc3.14138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38924339/&quot;>https://pubmed.ncbi.nlm.nih.gov/38924339</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BA01_1;
